MX2021011574A - Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. - Google Patents

Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.

Info

Publication number
MX2021011574A
MX2021011574A MX2021011574A MX2021011574A MX2021011574A MX 2021011574 A MX2021011574 A MX 2021011574A MX 2021011574 A MX2021011574 A MX 2021011574A MX 2021011574 A MX2021011574 A MX 2021011574A MX 2021011574 A MX2021011574 A MX 2021011574A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical compositions
compounds
novel compounds
inflammatory disorders
Prior art date
Application number
MX2021011574A
Other languages
English (en)
Inventor
Gregory John Robert Newsome
Reginald Christophe Xavier Brys
Oscar Mammoliti
Marielle Gilles Babel
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2021011574A publication Critical patent/MX2021011574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención describe compuestos de acuerdo con la Fórmula I: (ver Fórmula) en donde R1, R2 y Cy son como se definen en el presente documento. La presente invención se refiere a compuestos, a métodos para la producción de los compuestos, a composiciones farmacéuticas que comprenden los compuestos y a métodos para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinmunes, dolor, fibrosis y/o enfermedades proliferativas mediante la administración de los compuestos.
MX2021011574A 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. MX2021011574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MX2021011574A true MX2021011574A (es) 2021-10-13

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011574A MX2021011574A (es) 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.

Country Status (13)

Country Link
US (1) US20220296573A1 (es)
EP (1) EP3947374A1 (es)
JP (1) JP2022526553A (es)
KR (1) KR20210143905A (es)
CN (1) CN113677678A (es)
AU (1) AU2020252900A1 (es)
BR (1) BR112021019099A2 (es)
CA (1) CA3134732A1 (es)
GB (1) GB201904375D0 (es)
IL (1) IL286688A (es)
MX (1) MX2021011574A (es)
SG (1) SG11202110643YA (es)
WO (1) WO2020200898A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150626A1 (en) * 2019-01-18 2020-07-23 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
KR20230059584A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
CA2566184A1 (en) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
LT2970255T (lt) * 2013-03-14 2017-12-11 Galapagos Nv Uždegiminių sutrikimų gydymui skirti junginiai ir jų farmacinės kompozicijos
CA2935880A1 (en) * 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
JP6895439B2 (ja) * 2015-12-22 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020150626A1 (en) * 2019-01-18 2020-07-23 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors

Also Published As

Publication number Publication date
WO2020200898A1 (en) 2020-10-08
CN113677678A (zh) 2021-11-19
JP2022526553A (ja) 2022-05-25
EP3947374A1 (en) 2022-02-09
US20220296573A1 (en) 2022-09-22
IL286688A (en) 2021-10-31
GB201904375D0 (en) 2019-05-15
KR20210143905A (ko) 2021-11-29
BR112021019099A2 (pt) 2021-11-30
CA3134732A1 (en) 2020-10-08
AU2020252900A1 (en) 2021-11-25
SG11202110643YA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2020005423A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
WO2019007696A1 (en) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MY170260A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
MX2020013275A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.